DTIL
NASD Precision BioSciences, Inc.$6.72 ↑ +0.00 (+0.00%) Trading Up from the previous close of $6.72, $0.20 below the day’s high of $6.92
- YTD change
- +61.54%
- vs 20-day SMA
- +3.61%
- vs 200-day SMA
- +5.88%
Price ranges
Price & Performance
-0.18 (-2.72%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 99.1% away from all-time highs of $710.11
- DTIL is up 62% since the beginning of the year
- DTIL is up 14% over the past 12 months
- DTIL is down 7% over the past 1 month
- 8% of all DTIL investors are betting against DTIL
DTIL reads very good: price sits above both the 20- and 200-day averages, the 12-month move is +9.4%.
- Previous minute
- +$0.00
- Last hour
- +$0.00
- Last 5 days
- +6.16%
- vs 8-day SMA
- +6.94%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's proprietary genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane on January 26, 2006 and is headquartered in Durham, NC.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
